百时美施贵宝称一款淋巴瘤药物已获欧盟批准

环球市场播报

03-14

　　百时美施贵宝（Bristol Myers Squibb）周五宣布，欧盟委员会（EC）已批准Breyanzi®（利基迈仑赛）用于治疗接受过两线或以上系统治疗后复发或难治性滤泡性淋巴瘤（FL）的成年患者。

　　该决定基于全球2期TRANSCEND FL试验的结果，这是迄今为止评估CAR-T细胞疗法在复发或难治性惰性非霍奇金淋巴瘤（NHL）患者中疗效的最大规模临床试验。

　　Breyanzi显示出持久的临床效益，75.7%的患者在18个月时仍有反应，且安全性一致，未观察到新的安全信号。

　　百时美施贵宝欧洲地区高级副总裁艾玛·查尔斯（Emma Charles）表示：“Breyanzi在佛罗里达州之外得到额外批准，标志着我们在向欧洲更多患者提供细胞疗法变革性承诺的使命中迈出了关键一步。”

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2519389490"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519389490\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2519389490?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-03-14 23:28","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2519389490","market":"sh","top_or_hot":-1,"title":"百时美施贵宝称一款淋巴瘤药物已获欧盟批准","media":"环球市场播报","content":"<html><body><div>\n<p>　　百时美<span><a href=\"https://laohu8.com/S/BMY\">施贵宝</a></span><span></span>（Bristol Myers Squibb）周五宣布，欧盟委员会（EC）已批准Breyanzi®（利基迈仑赛）用于治疗接受过两线或以上系统治疗后复发或难治性滤泡性淋巴瘤（FL）的成年患者。</p>\n<div><img src=\"https://n.sinaimg.cn/tech/transform/119/w550h369/20250314/cd2d-1d4d009374e02d0b259bc9d44d2f7fb0.png\"/><span></span></div>\n<p>　　该决定基于全球2期TRANSCEND FL试验的结果，这是迄今为止评估CAR-T细胞疗法在复发或难治性惰性非霍奇金淋巴瘤（NHL）患者中疗效的最大规模临床试验。</p>\n<p>　　Breyanzi显示出持久的临床效益，75.7%的患者在18个月时仍有反应，且安全性一致，未观察到新的安全信号。</p>\n<p>　　百时美施贵宝欧洲地区高级副总裁艾玛·查尔斯（Emma Charles）表示：“Breyanzi在佛罗里达州之外得到额外批准，标志着我们在向欧洲更多患者提供细胞疗法变革性承诺的使命中迈出了关键一步。”</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在新浪财经APP</div>\n</div>\n<p>责任编辑：张俊 SF065</p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百时美施贵宝称一款淋巴瘤药物已获欧盟批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百时美施贵宝称一款淋巴瘤药物已获欧盟批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-14 23:28 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2025-03-14/doc-inepryri6533396.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>百时美施贵宝（Bristol Myers Squibb）周五宣布，欧盟委员会（EC）已批准Breyanzi®（利基迈仑赛）用于治疗接受过两线或以上系统治疗后复发或难治性滤泡性淋巴瘤（FL）的成年患者。\n\n　　该决定基于全球2期TRANSCEND FL试验的结果，这是迄今为止评估CAR-T细胞疗法在复发或难治性惰性非霍奇金淋巴瘤（NHL）患者中疗效的最大规模临床试验。\n　　Breyanzi显示出持久...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2025-03-14/doc-inepryri6533396.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-03-14/doc-inepryri6533396.shtml","article_id":"2519389490","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519389490","pubTimestamp":1741966080,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"百时美施贵宝周五宣布，欧盟委员会已批准Breyanzi用于治疗接受过两线或以上系统治疗后复发或难治性滤泡性淋巴瘤的成年患者。　　Breyanzi显示出持久的临床效益，75.7%的患者在18个月时仍有反应，且安全性一致，未观察到新的安全信号。　　百时美施贵宝欧洲地区高级副总裁艾玛·查尔斯表示：“Breyanzi在佛罗里达州之外得到额外批准，标志着我们在向欧洲更多患者提供细胞疗法变革性承诺的使命中迈出了关键一步。”","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4559":"巴菲特持仓","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","BK4588":"碎股","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4581":"高盛持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","BK4532":"文艺复兴科技持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BMY":"施贵宝","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0237698245.USD":"富达环球地产基金A","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC"},"translate_title":"Bristol-Myers Squibb says a lymphoma drug has been approved by the EU","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1},"content_text":"百时美施贵宝（Bristol Myers Squibb）周五宣布，欧盟委员会（EC）已批准Breyanzi®（利基迈仑赛）用于治疗接受过两线或以上系统治疗后复发或难治性滤泡性淋巴瘤（FL）的成年患者。\n\n　　该决定基于全球2期TRANSCEND FL试验的结果，这是迄今为止评估CAR-T细胞疗法在复发或难治性惰性非霍奇金淋巴瘤（NHL）患者中疗效的最大规模临床试验。\n　　Breyanzi显示出持久的临床效益，75.7%的患者在18个月时仍有反应，且安全性一致，未观察到新的安全信号。\n　　百时美施贵宝欧洲地区高级副总裁艾玛·查尔斯（Emma Charles）表示：“Breyanzi在佛罗里达州之外得到额外批准，标志着我们在向欧洲更多患者提供细胞疗法变革性承诺的使命中迈出了关键一步。”\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}